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SHORT COMMUNICATION
Interleukin-18 mediates cardiac dysfunction induced by
western diet independent of obesity and hyperglycemia in
the mouse
S Carbone1,2,3, PJH Lee1,2, AG Mauro1,2, E Mezzaroma1,2,4, R Buzzetti3, B Van Tassell2,4, A Abbate1,2 and S Toldo1,2
Obesity and diabetes are independent risk factors for heart failure and are associated with the consumption of diet rich in saturated
fat and sugar, Western diet (WD), known to induce cardiac dysfunction in the mouse through incompletely characterized
inflammatory mechanisms. We hypothesized that the detrimental cardiac effects of WD are mediated by interleukin-18 (IL-18), pro-
inflammatory cytokine linked to cardiac dysfunction. C57BL/6J wild-type male mice and IL-18 knockout male mice were fed high-
saturated fat and high-sugar diet for 8 weeks. We measured food intake, body weight and fasting glycemia. We assessed left
ventricular (LV) systolic and diastolic function by Doppler echocardiography and cardiac catheterization. In wild-type mice, WD
induced a significant increase in isovolumetric relaxation time, myocardial performance index and left ventricular end-diastolic
pressure, reflecting an impairment in diastolic function, paired with a mild reduction in LV ejection fraction. IL-18 KO mice had
higher food intake and greater increase in body weight without significant differences in hyperglycemia. Despite displaying greater
obesity, IL-18 knockout mice fed with WD for 8 weeks had preserved cardiac diastolic function and higher left ventricular ejection
fraction. IL-18 mediates diet-induced cardiac dysfunction, independent of food intake and obesity, thus highlighting a disconnect
between the metabolic and cardiac effects of IL-18.
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INTRODUCTION
The epidemic in obesity and diabetes has been linked to the
consumption of a diet rich in saturated fat and sugars, Western
diet (WD), which is by itself able to induce obesity, diabetes, and
cardiac systolic and diastolic dysfunction in animals.1 The
molecular mechanisms involved in the diet-induced cardiac
dysfunction are largely unknown.
Systemic inflammation negatively affects cardiac function, and
predicts exercise capacity and hospital readmission in patients
with heart failure.2,3 The pro-inflammatory interleukin (IL)-18
is a cytokine of the interleukin-1 family that is abundant in the
heart and is involved in the development and progression of
cardiac hypertrophy, remodeling and failure.4,5 In vitro studies
suggest that specific nutrients such as saturated fat and sugars
can increase the production of IL-18 through direct activation
of the intracellular macromolecular complex Nod-like receptor
pyrin domain-containing protein 3 (NLRP3) inflammasome.6–12
IL-18, on the other hand, also regulates hunger and satiety, body
weight and composition, and glucose metabolism, and it
opposes obesity and insulin resistance.13 IL-18 may therefore
represent the missing link between a pro-inflammatory diet,
that is, WD, and cardiac dysfunction.1,14 In this study, we
measured cardiac and systemic effects of WD in mice with
IL-18 genetic deletion (IL-18 KO) testing two competing
hypotheses, one by which deletion of IL-18 would promote
greater food intake and weight gain, thus enhancing the
negative impact of WD on cardiac function, and the alter-
native hypothesis by which deletion of IL-18 will protect the
heart from the negative effects of WD, thus preserving cardiac
function.
MATERIALS AND METHODS
Experiments were conducted in 8- to 10-week old male
genetically modified mice lacking the gene for IL-18 (IL-18
knockout (KO) mice) (Jackson Laboratories, Bar Harbor, ME, USA)
and age-matched C57BL/6J wild-type (WT) male mice (Envigo,
Madison, WI, USA). A group of age-matched male CD1 WT mice
(Envigo) was used to measure IL-18 mRNA in the heart (real-time
PCR, SYBR Green PCR master mix; Life Technologies, Carlsbad,
CA, USA) and IL-18 serum levels (ELISA, Quant; Bio-Tek,
Winooski, VT, USA) after 8 weeks of WD (TD.88137; Envigo)
compared with Standard diet (Teklad LM-485; Envigo).
We fed IL-18 KO and WT mice with WD (TD.88137; Envigo)
providing unlimited access to food.1 Food intake was measured
daily, body weight weekly. Capillary glucose was obtained from
the tail at baseline and 8 weeks (Clarity Diagnostics, Boca Raton,
FL, USA), after 8–10 h fasting.
Mice underwent transthoracic Doppler echocardiography
(Vevo770; VisualSonics, Toronto, ON, Canada) under sedation
(30–50 mg kg− 1 pentobarbital) at baseline, 4 and 8 weeks.1 Left
ventricular (LV) catheterization with a retrograde right carotid
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artery approach (Millar Inc., Houston, TX, USA) to measure LV end-
diastolic pressure (LVEDP) was performed at 8 weeks under
anesthesia (50–70 mg kg− 1 pentobarbital), prior to killing.1 The
hearts were explanted to measure LV interstitial fibrosis using
Masson’s trichrome (Sigma-Aldrich, St Louis, MO, USA) computer
morphometric analysis (Image ProPlus 6.0 software, Media
Cybernetics, Rockville, MD, USA).1 Values were expressed as the
mean and standard error of the mean. The statistical analysis was
performed using SPSS 22.0 (IBM Corp., Armonk, NY, USA).
Differences within each group or between groups were analyzed
using the Student’s T-test for paired and unpaired data,
respectively. A sample size of 6 or more for each group provided
a power 480% (α= 0.05) to detect a meaningful difference
defined as difference between means exceeding the standard
deviation in each group. No animals or samples were excluded
from the data analysis. The investigators performing echocardio-
graphy or samples analyses were blinded to the treatment
allocations and genotype of the animals. The investigator feeding
and handling mice kept other investigators blinded to the
treatment and the genotype. No randomization was performed.
All studies were approved by the Virginia Commonwealth
University Institutional Animal Care and Use Committee and
conducted according to the NIH guidelines.
RESULTS
Compared with mice fed standard diet, WD significantly increased
IL-18 plasma levels (+35%, P= 0.01) and IL-18 cardiac mRNA
expression (+127%, P= 0.04) (Supplementary Figure S1). There
were no significant differences in cardiac or metabolic parameters
between IL-18 KO and WT mice at baseline (Supplementary
Figure S2). IL-18 KO mice on WD had a higher 8-week cumulative
caloric intake (804 ± 2 vs 765 ± 10 kcal, Po0.001; Figure 1a) and
weight gain (+38.8% vs +20.0%, Po0.001; Figure 1b), without
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Figure 1. Interleukin-18 (IL-18) paradox in diet-induced obesity and cardiac dysfunction. Interleukin-18 (IL-18) knockout (KO) mice
had a higher food intake (a) and body weight (b), and similar glucose (c) compared with wild type. IL-18 KO mice presented partially
preserved systolic (d) and diastolic function (e–g) and less myocardial interstitial fibrosis (h). #Po0.05 vs wild type; *Po0.05 vs
Baseline.
Interleukin-18, obesity and cardiac function
S Carbone et al
2
Nutrition & Diabetes (2017) 1 – 4
significant differences in fasting glycemia (152 ± 32 vs
184 ± 49 mg dl− 1, P= 0.13; Figure 1c).
Despite higher caloric intake and weight gain, IL-18 KO mice
showed a significantly greater preservation of LV ejection fraction
(Figure 1d), reflecting better systolic function, and shorter
isovolumetric relaxation time (Figure 1e), lower myocardial
performance index (Figure 1f) and lower LVEDP (Figure 1g),
reflecting better diastolic function compared with WT mice fed
with the same WD. Myocardial interstitial fibrosis was also
significantly less in KO compared with WT mice (Figure 1h).
DISCUSSION
These results show the complexity of IL-18 signaling in cardiac
function and metabolism. WD impairs cardiac function and
promotes obesity through distinct signaling pathways. IL-18
mediates cardiac systolic and diastolic dysfunction induced by
WD, providing the possible missing link between the two. IL-18,
however, does not mediate the impairment in metabolism nor
promotes weight gain seen with WD, while it actually appears to
limit these changes.13 The disconnect between body weight and
cardiac function in IL-18 KO mice fed with WD suggests the
existence of an 'IL-18-paradox' possibly due to the presence of two
different signaling pathways: one leading to cardiac dysfunction
and dependent upon IL-18 and one leading to weight gain which
is independent of, and actually improved by, IL-18.13 Mice with
genetic deletion of Nod-like receptor pyrin domain-containing
protein 3 (NLRP3), the sensor in the NLRP3 inflammasome
responsible for the processing of IL-18 and of IL-1β, and mice
with genetic deletion of IL-1 have preserved cardiac function and
reduced weight gain compared with wild-type mice fed WD,15–18
thus suggesting a hierarchy in the response to systemic
inflammation by which IL-1β mediates the cardiac effects through
activation of IL-18 in the heart5 and a systemic response that is, at
least in part, independent of IL-18 in this model.
This may occur through two different signaling pathways, one
in the brain regulating food intake13 and one in the heart
regulating cardiac function4 (Figure 2). Systemically administered
IL-18, indeed, impairs cardiac function,5 but does not affect food
intake,13 and IL-18 limits food intake only if administered directly
in the brain.13
The association of obesity and metabolic abnormalities with HF
is object of intense investigation, particularly suggesting that
obesity causes HF ('obesity cardiomyopathy') and that weight loss
would cure HF.19 However, obesity may also be considered a co-
morbid condition that further limits exercise capacity in HF
without directly affecting cardiac function.20
IL-18 KO mice had better cardiac function despite greater
weight gain, showing that in response to WD, obesity and cardiac
dysfunction occur simultaneously, yet the former is not the cause
for the latter.
The observation that IL-18 KO mice are obese yet have
better cardiac function than the leaner WT mice is vaguely
reminiscent of the 'obesity paradox' in patients with HF, by which
patients with HF and are obese tend to have a more favorable
prognosis.21,22
From a translational standpoint, IL-18-targeted strategies
may be valuable in preventing or treating heart failure.4,23 An
IL-18-blocking antibody and recombinant IL-18 binding protein,
which binds circulating IL-18 preventing it from binding to the
membrane receptor, are being developed as clinical therapeutics.
Of note, in preclinical studies5,22 and in phase I and II clinical
trials,24,25 these inhibitors did not impair metabolism nor induce
weight gain. This is in contrast with the data from the IL-18 KO
mouse model.13 This substantial difference likely lies in the
different IL-18 signaling in the brain, with the IL-18 KO mouse
lacking IL-18 throughout the body, including the brain, whereas
the antibody and the binding protein fail to cross the blood brain
barrier and penetrate the brain and hence have no effect on food
intake and weight gain. Similar findings would be expected to be
seen in obese subjects, in which we believe that treatment
with IL-18-binding protein or IL-18 antibody would still exert
beneficial effects on the heart, without inducing an increase in
food intake, body weight and impairment in glucose metabolism.
A recent pilot study in obese subjects with type 2 diabetes treated
with IL-18 antibody for 12 weeks has shown a safe profile of the
drug, tested at different doses, without impairing glucose
metabolism.24
In our study, mice were fed WD for 8 weeks based on our prior
study where 4 and 8 weeks of WD induced a significant cardiac
dysfunction.1 We cannot exclude that the cardiac dysfunction
induced by WD and the protective effects of IL-18 deletion would
differ if mice were fed high-saturated fat and high-sugar diet for a
longer period, in which metabolic abnormalities will likely become
more prominent. Moreover, we have not measured the levels of
other cytokines that may also be involved in the cardiac
dysfunction induced by WD and potentially be affected by
genetic deletion of IL-18. However, in a prior study the
preservation of cardiac function seen in IL-18 KO mouse or after
IL-18 blockade therapy did not affect IL-6 plasma levels,
suggesting that the protective effects on the heart were
independent of IL-6.5
Finally, we did not measure the level of oxidative stress induced
by high-sugar and high-saturated fat diet, which has also been
reported to affect the heart by directly impairing cardiac
contractile function,26 and how the genetic deletion of IL-18
affected such parameters.
In conclusion, IL-18 mediates the cardiac dysfunction
induced by a high-saturated fat and high-sugar diet, independent
Figure 2. Disconnect between the effects of IL-18 deletion on the
heart and on metabolism. The disconnect between the effects of
IL-18 deletion on the heart and on metabolism suggests the
presence of two possible independent pathways: (1) a metabolic
pathway, mediated by the central nervous system (CNS), with
negative effects of IL-18 deletion on metabolism by increasing food
intake, body weight and glucose and (2) a cardiac pathway, with
direct protective effect of IL-18 deletion on the heart function by
improvement of systolic and diastolic function, and reducing
interstitial fibrosis.
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of food intake, obesity and hyperglycemia, showing a disconnect
between diet-induced obesity, altered metabolism and cardiac
dysfunction.
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